Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gwin

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Vaccines|February 26, 2025
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast CancerWilliam R Gwin, Lupe G Salazar, James Y Dai, et al.
Journal for Immunotherapy of Cancer|November 12, 2020
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratioErika J Crosby, Amy C Hobeika, Donna Niedzwiecki, et al.
Breast Cancer Research : BCR|August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancersTakuya Osada, Zachary C Hartman, Junping Wei, et al.
Oncoimmunology|July 7, 2017
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibitionTakuya Osada, Michael A Morse, Amy Hobeika, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Oncoimmunology|May 17, 2017
Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapyJun Ren, William R Gwin, Xinna Zhou, et al.
The Breast Journal|June 28, 2026
Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast CancerPoorni M Manohar, Veena Shankaran, Nancy E Davidson, et al.
Communications Biology|May 10, 2020
Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumorsKensuke Kaneko, Takuya Osada, Michael A Morse, et al.
Gynecologic Oncology|October 3, 2024
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancerJohn B Liao, Nikita S Jejurikar, Katie M Hitchcock-Bernhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective StudyNi Jiang, Guoliang Qiao, Xiaoli Wang, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Vaccines|February 26, 2025
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast CancerWilliam R Gwin, Lupe G Salazar, James Y Dai, et al.
Journal for Immunotherapy of Cancer|November 12, 2020
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratioErika J Crosby, Amy C Hobeika, Donna Niedzwiecki, et al.
Breast Cancer Research : BCR|August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancersTakuya Osada, Zachary C Hartman, Junping Wei, et al.
Oncoimmunology|July 7, 2017
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibitionTakuya Osada, Michael A Morse, Amy Hobeika, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Oncoimmunology|May 17, 2017
Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapyJun Ren, William R Gwin, Xinna Zhou, et al.
The Breast Journal|June 28, 2026
Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast CancerPoorni M Manohar, Veena Shankaran, Nancy E Davidson, et al.
Communications Biology|May 10, 2020
Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumorsKensuke Kaneko, Takuya Osada, Michael A Morse, et al.
Gynecologic Oncology|October 3, 2024
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancerJohn B Liao, Nikita S Jejurikar, Katie M Hitchcock-Bernhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective StudyNi Jiang, Guoliang Qiao, Xiaoli Wang, et al.
Pageof 3